RxDoctor Payments Data

Ryan Wong, MD

Retina Specialist · Tucson, AZNPI 1922234798

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Alimera Sciences, Inc. at 35.8% of the total. Reporting peaked in 2022 at $1,441 and has fallen 55.5% since, to $642 in 2025. That places this record below the midpoint for retina specialist clinicians in AZ, where the typical reported total is $12,789.

$5,134in general payments, 2019–2025

Across 82 payments — averaging $62.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alimera Sciences, Inc.$2K
  • Novartis$548
  • Regeneron Healthcare Solutions, Inc.$528
  • Alcon$435
  • Genentech USA, Inc.$340
  • Glaukos Corporation$312
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$5,134100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,134 in reported general payments places this provider in the 25th percentile of 30 retina specialist providers in Arizona.

See all retina specialist providers in Arizona

Medicare billing

Part B allowed, 2024
$4,292,657
Medicare patients
1,276
Services billed
53,749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate210$9,485
IlevroNepafenac16$8,387
Ketorolac Tromethamine123$3,651
Dorzolamide Hcl52$858
Gentamicin Sulfate85$749
Brimonidine Tartrate34$537
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat48$485
Diclofenac Sodium14$276
ErythromycinErythromycin Base14$142
Timolol Maleate16$90
Cyclopentolate Hcl11$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisIlevro$548$8,38716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 30 retina specialist providers in Arizona.

Other retina specialist in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →